Articles On Immutep (ASX:IMM)

Title Source Codes Date
The A to Z of Dr Boreham’s Crucible in 2022

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

Stockhead IMM 2 years ago
In Brief: Insurers, Healthcare, Contractors, Classifieds, Retail 

Weekly broker wrap: insurers more resilient, healthcare picks, contractors remain labour-reliant, classifieds look resilient, retail braces for decline. -Climate resilience supports domestic insurance outlook-Wilsons lists healthcare sector...

FNArena IMM 2 years ago
Lithium slammed by GS, NSW close to energy deal with Federal Government: ASX closes 0.6% lower

ShareCafeLithium slammed by GS, NSW close to energy deal with Federal Government: ASX closes 0.6% lower by Peter Milios   Goldman Sachs have extended their bearish views on lithium, believing that the prices are expected to decline from the...

ShareCafe IMM 2 years ago
Lithium stocks under pressure following Goldman’s comments: ASX down 0.47% at noon

ShareCafeLithium stocks under pressure following Goldman’s comments: ASX down 0.47% at noon by Lauren Hayes   The Australian market is still unnerved over concerns about a possible US recession. Energy is weighing down the benchmark over fe...

ShareCafe IMM 2 years ago
Immutep (ASX:IMM) achieves commercial scale manufacturing of efti

Immutep (IMM) achieves commercial scale manufacturing of its lead product candidate, eftilagimod alpha (efti)The company completed its first 2000-litre manufacturing run of efti, a first-in-class soluble LAG-3 proteinImmutep has been workin...

themarketherald.com.au IMM 2 years ago
ASX Health Stocks: Imagion jumps 20pc after delivering positive Phase 1 results

Imagion presents positive data at world leading symposium Osteopore expands in Southeast Asia Microba expands into Italy and Portugal   Imagion speaks at world-leading breast cancer symposium Imagion Biosystems (ASX:IBX) is set to rise ov...

Stockhead IMM 2 years ago
Shares dip following rate hike: ASX closes 0.5% lower

ShareCafeShares dip following rate hike: ASX closes 0.5% lower by Peter Milios   The ASX has closed 0.47 per cent lower after the Reserve Bank of Australia delivered its eighth interest rate hike in a row, lifting the cash rate 25 basis hig...

ShareCafe IMM 2 years ago
Local market awaits RBA rate decision: ASX falls 0.17% at noon

ShareCafeLocal market awaits RBA rate decision: ASX falls 0.17% at noon by Lauren Hayes   The Australian market has followed Wall Street’s negative lead overnight after US markets sold off on fears that the Fed will keep increasing interest...

ShareCafe IMM 2 years ago
Market Highlights: Rates day! And almost every US stock loses overnight as US economy picks up

Well, it’s rates day here in Oz, and property owners are donning their brownest pants for a likely rise. Some say 50bps is sensible. In the US, the Fed got a case to keep rising rates despite the inflationary slowdown. Stronger than expecte...

Stockhead IMM 2 years ago
The Week that Was: November 28-December 2, 2022

ShareCafeThe Week that Was: November 28-December 2, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier...

ShareCafe IMM 2 years ago
ScoPo’s Powerplays: ASX health stocks dancing to a positive tune

ASX Health sector is continuing its upward trend, marginally up this week 0.87%  Sonic Healthcare announces a plan to acquire ~20% holding of Microba Life Sciences Mayne Pharma shares takes a hit after company warns it won’t hit positive e...

Stockhead IMM 2 years ago
Iron ore climbs to highest price since September: ASX closes 0.3% higher

ShareCafeIron ore climbs to highest price since September: ASX closes 0.3% higher by Peter Milios   Singaporean iron ore futures have soared above the US$100 per tonne for the first time since September, resulting in gains for ASX-listed ir...

ShareCafe IMM 2 years ago
Immutep (ASX:IMM) enters second collaboration with Pfizer and Merck KGaA for INSIGHT study

Immutep (IMM) signs another collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a phase one clinical studyThe companies will conduct and jointly fund the INSIGHT-005 trial in Germany to evaluate Immutep’s efti product...

themarketherald.com.au IMM 2 years ago
Chinese protests over lockdowns continue: Aus shares 0.07% lower at noon

ShareCafeChinese protests over lockdowns continue: Aus shares 0.07% lower at noon by Peter Milios   The global economic outlook is shaky, as growing protests in the world’s largest manufacturing nation are creating a new level of uncertaint...

ShareCafe IMM 2 years ago
ASX Health Stocks: Sonic snaps up stake in Microba, sending MAP share price 60pc higher

Sonic has taken a stake in Microba Immutep enters into second deal with Merck (Germany) and Pfizer  ImpediMed has a new CEO   Sonic takes strategic stake in Microba Giant healthcare stock Sonic Healthcare (ASX:SHL) has bought a stake in s...

Stockhead IMM 2 years ago
Immutep announces new collaboration for cancer treatment combination

Immutep (ASX:IMM) has announced a new clinical trial collaboration under which the Australian company's investigative LAG-3 immunotherapy, efti, will be studied with Merck and Pfizer's PBS-listed BAVENCIO (avelumab).

BiotechDispatch IMM 2 years ago
Market Highlights: China protests dampen investor mood, and 5 ASX small caps to watch on Tuesday

The ASX is set to open slightly higher on Tuesday Wall Street fell almost 2% overnight as protests in China spread Crypto lender BlockFi has filed for bankruptcy The ASX is poised to edge slightly higher on Tuesday despite a 1.5% – 1.75%...

Stockhead IMM 2 years ago
Immutep (ASX: IMM) – A Transformative Year for LAG-3 Therapies

ShareCafeImmutep (ASX: IMM) – A Transformative Year for LAG-3 Therapies Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company’s portfolio of therapies, encouraging data from the 2022 SIT...

ShareCafe IMM 2 years ago
How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Stockhead IMM 2 years ago
Early gains quickly wiped off: ASX closes the day 0.16% lower

ShareCafeEarly gains quickly wiped off: ASX closes the day 0.16% lower by Peter Milios   All sectors except Materials and Energy are lower in today’s day of trading, as the ASX finishes 0.16 per cent or 11.70 points lower at 7146.30. Materi...

ShareCafe IMM 2 years ago
ASX Close: Shares fade as global rally falters

The ASX gave up early gains as last week’s fierce global share rally showed signs of losing momentum.   The S&P/ASX 200 touched a five-month high before fading to a loss of 12 points or 0.16 per cent. The decline came as Asian mar...

themarketherald.com.au IMM 2 years ago
Market losing momentum, materials the saviour: ASX flat at noon

ShareCafeMarket losing momentum, materials the saviour: ASX flat at noon by Lauren Hayes   Last week’s gains have not continued with the same momentum this morning. Materials, up 3.4 per cent, is bolstering the local market following a rise...

ShareCafe IMM 2 years ago
ASX Update: Early gains evaporate as Fed talks down outlook

The share market touched a five-month high before shedding its gains as a decline in US futures undermined a China-fuelled rally in resource stocks. The S&P/ASX 200 rallied to within four points of 7200 for the first time since June....

themarketherald.com.au IMM 2 years ago
Immutep (ASX:IMM) receives $986k R&D tax rebate

Immutep (IMM) receives a $986,000 tax refund from the Australian government’s research and development (R&D) tax incentive programThe cash rebate is mostly for money Immutep spent on its clinical study work during its 2021 financial yea...

themarketherald.com.au IMM 2 years ago
ASX 200 rises at open; Fortescue, Champion Iron up over 8%

Highlights Australian shares opened higher on Monday. The ASX 200 gained in the opening trade, rising 25.20 points, or 0.35%, to 7,183.20. On Friday, the benchmark index closed 2.8% higher at 7,158 points. Australian s...

Kalkine Media IMM 2 years ago
Imugene (ASX:IMU) presents fresh onCARlytics data at SITC annual meeting

Imugene (IMU) presents new data for its onCARlytics oncolytic virus at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, USThe company presented two different sets — the first for a treatment with fellow biotec...

themarketherald.com.au IMM 2 years ago
Immutep (ASX:IMM) granted Japanese and South Korean patents for efti

Immutep (IMM) receives two new patents from the Japanese Patent Office and South Korean Patent Office for its immunotherapy treatment for cancerThe new patent protects Immutep’s intellectual property relating to combined therapeutic prepara...

themarketherald.com.au IMM 2 years ago
A sea of red in today’s trading: ASX closes 1.84% lower

ShareCafeA sea of red in today’s trading: ASX closes 1.84% lower by Peter Milios   All but one sector finished lower today, as the ASX reacted to the overnight news that the Fed has increased rates by 75 basis points. Materials, Consumer Di...

ShareCafe IMM 2 years ago
All red across the board following US rate hike sentiment: ASX down 1.96% at noon

ShareCafeAll red across the board following US rate hike sentiment: ASX down 1.96% at noon By Lauren Hayes   US equities plunged after Fed Chair Jerome Powell indicated policymakers would continue raising interest rates to fight persistent...

ShareCafe IMM 2 years ago
2 ASX healthcare shares smashing the All Ords today

The All Ordinaries Index (ASX: XAO) may be sinking today but that hasn’t stopped a couple of ASX healthcare shares from racing higher. Here’s why these two All Ords shares are smashing the index on Thursday: Immutep Ltd (ASX: IMM) The...

Motley Fool IMM 2 years ago
ASX Health Stocks: HitIQ soars 40pc after signing footy deal; Rhythm Bio expands to NZ

HitIQ signs deal with Western Australian Football Commission Rhthym Bio expands into NZ Immutep’s Phase II TACTI-002 trial has been accepted for an oral presentation HitIQ signs with WAFC Concussion tech specialist HitIQ (ASX:HIQ) rose 40...

Stockhead IMM 2 years ago
Market Highlights: Two uttered words that crashed the market, and 5 ASX small caps to watch today

The ASX is set to plunge on Thursday after a crash in New York US Fed unleashed another jumbo 75bp rate hike Fed boss Jerome Powell spooked the markets during his speech   The ASX is poised to plunge on Wednesday, tracking movements in Ne...

Stockhead IMM 2 years ago
ASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon

ShareCafeASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon by Peter Milios   Last week’s rally for US equities ground to a halt overnight ahead of this week’s Federal Reserve decision on interest rates, as te...

ShareCafe IMM 2 years ago
Immutep (ASX:IMM) to continue with controlled phase IIB TACTI-003 trial for HNSCC cancer

Immutep (IMM) is given approval by the Independent Data Monitoring Committee (IDMC) to carry on with its planned phase IIb TACTI-003 trialThe IDMC reviewed the initial safety data and concluded that the trial should continue with no modific...

themarketherald.com.au IMM 2 years ago
Market unfazed by CPI data: ASX finishes 0.18% higher

ShareCafeMarket unfazed by CPI data: ASX finishes 0.18% higher by Peter Milios   CPI data from the September quarter has sharply exceeded estimates. As such, multiple banks have made predictions for the next rate rise. Commonwealth Bank (AS...

ShareCafe IMM 2 years ago
Australian headline inflation hits highest in 32 years: ASX up 0.12% at noon

ShareCafeAustralian headline inflation hits highest in 32 years: ASX up 0.12% at noon by Lauren Hayes   The S&P/ASX 200 posted gains this morning as sentiment from Wall Street overnight improved over the Fed potentially turning less agg...

ShareCafe IMM 2 years ago
ASX Biotech Stocks: Neurotech reports positive paediatric autism results and Arovella to close Perth R&D facility

Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A...

Stockhead IMM 2 years ago
Energy and Materials only sectors left lagging: ASX closes 0.28% higher

ShareCafeEnergy and Materials only sectors left lagging: ASX closes 0.28% higher by Peter Milios   In today’s events, independent commission agency ASIC has launched legal action against BPS Financial, the company behind Gold Coast-based di...

ShareCafe IMM 2 years ago
Optimism out of the US boosts sentiment: ASX up 0.6% at noon

ShareCafeOptimism out of the US boosts sentiment: ASX up 0.6% at noon by Lauren Hayes   Positive gains in the local market have extended into a second day as optimism out of the US about corporate earnings ahead of several key tech reports...

ShareCafe IMM 2 years ago
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Stockhead IMM 2 years ago
Immutep (ASX: IMM) Receives Fast Track Designation from FDA

ShareCafeImmutep (ASX: IMM) Receives Fast Track Designation from FDA   Immutep Limited (ASX: IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company...

ShareCafe IMM 2 years ago
Trading Places: Chinese mining giant backs Tietto Minerals and LGI’s new substantial shareholders

Emerging gold miner Tietto Minerals has a new Chinese Mining giant as a substantial shareholder Environment play LGI has new substantial shareholders since listing on the ASX last week Lunnon Metals loses substantial shareholders while Bas...

Stockhead IMM 2 years ago
ScoPo’s Powerplays: Calmer week for ASX health stocks with some alarming stats about how many people drink instant coffee

During latest period of volatility many health stocks have seen their share prices remain quite stable Several ASX health stocks have rallied this week on positive news including Polynovo on $5 million sales month Telix Pharmaceuticals ral...

Stockhead IMM 2 years ago
Energy’s advancements just enough to lift the ASX: Aus shares close 2.2% higher

ShareCafeEnergy’s advancements just enough to lift the ASX: Aus shares close 2.2% higher by Peter Milios   The ASX’s two-day positive run has turned to three days. It finished the day having increased slightly by 0.03 per cent or 1.80 point...

ShareCafe IMM 2 years ago
Second fast-track designation for Australian immunotherapy company

Australian immunotherapy company Immutep has secured fast-track designation from the US FDA for its eftilagimod alpha for use in combination with MSD's KEYTRUDA (pembrolizumab).

BiotechDispatch IMM 2 years ago
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Stockhead IMM 2 years ago
Immutep (ASX:IMM) receives FDA Fast Track designation for NSCLC treatment

Immutep (IMM) receives US FDA Fast Track designation for its efti drug candidate as a treatment for non-small cell lung cancer (NSCLC)The designation — Immutep’s second for the drug — is specifically for efti when used in combination with c...

themarketherald.com.au IMM 2 years ago
ASX Health Stocks: Paradigm soars 19pc after meeting primary endpoint of Phase 2 trial

Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t...

Stockhead IMM 2 years ago
Why did the Imugene share price implode 31% in September?

The Imugene Limited (ASX: IMU) share price had a rough month despite multiple clinical trial updates. Imugene shares have fallen 30.77% from 26 cents at market close on 31 August to 18 cents at market close on 30 September....

Motley Fool IMM 2 years ago
Immutep (ASX:IMM) receives $2.7 million R&D French tax incentive

Immutep (IMM) receives a $2.7 million research and development tax incentive from the French GovernmentThe company received the funds under France’s research tax credit scheme, which sees eligible French companies reimbursed for 30 per cent...

themarketherald.com.au IMM 2 years ago